Drug Type Probiotics |
Synonyms VSL#3, VSL-3 |
Target- |
Action modulators |
Mechanism Bacteria replacements, Microbiome modulators |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Live lactic acid bacteria probiotics(Vsl Pharmaceuticals, Inc.) | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Colitis, Ulcerative | - | - | |
Irritable Bowel Syndrome | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pediatric Crohn's Disease | Phase 3 | United States | 01 Jul 2009 | |
Crohn Disease | Phase 3 | Canada | 01 Dec 2003 | |
Decompensated cirrhosis of liver | Phase 2 | United Kingdom | 01 Feb 2012 | |
Spontaneous bacterial peritonitis | Phase 2 | United Kingdom | 01 Feb 2012 |
Phase 2 | 62 | placebo+VSL#3 (VSL#3 Probiotic) | cdurmasiia = iziwbedpdt ndvktnfegr (elyrjlwzth, fdjaaixczs - owjadbwqcb) View more | - | 19 Jul 2016 | ||
placebo (Placebo) | cdurmasiia = ochdqjwvrf ndvktnfegr (elyrjlwzth, jsakugpztu - afdcwbczig) View more | ||||||
Not Applicable | Multiple Sclerosis pro-inflammatory cytokines IL-17 | IFN-γ | anti-inflammatory cytokine IL-10 | 15 | bqxqywyawy(cturavwxpp) = tazydwidqo tyxryawgbo (szchqczilm ) View more | Positive | 05 Apr 2016 | ||
Placebo | bqxqywyawy(cturavwxpp) = wanclxfxhn tyxryawgbo (szchqczilm ) View more |